ArticlePediatric diabetes2014
Improving prediction of type 1 diabetes by testing non-HLA genetic variants in addition to HLA markers.
Article in Pediatric diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 64 citations in OpenAlex.
- Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes.Journal of translational medicine · 2016Trial
- Development and application of type 1 diabetes polygenic scores across diverse populations.Diabetologia · 2026Review
- Imaging mass cytometry reveals functional and immunological changes during type 1 diabetes progression in human pancreata.Nature metabolism · 2026Article
- Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention.Diabetes care · 2026Article
- Genetic Risk and Transition Through Preclinical Stages of Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2026Article
- Early Detection of Type 1 Diabetes in First-Degree Relatives in Saudi Arabia (VISION-T1D): Protocol for a Pilot Implementation Study.JMIR research protocols · 2025Article
- The stage- and subgroup-specific impact of non-HLA polymorphisms on preclinical type 1 diabetes progression.Heliyon · 2025Article
- Type 1 Diabetes Genetic Risk Scores: History, Application and Future Directions.Current diabetes reports · 2025Review
- Genetic and Epigenetic Aspects of Type 1 Diabetes Mellitus: Modern View on the Problem.Biomedicines · 2024Review
- Emerging therapeutic options in the management of diabetes: recent trends, challenges and future directions.International journal of obesity (2005) · 2023Review
- Type 1 diabetes in diverse ancestries and the use of genetic risk scores.The lancet. Diabetes & endocrinology · 2022Review
- Non-HLA Gene Polymorphisms in the Pathogenesis of Type 1 Diabetes: Phase and Endotype Specific Effects.Frontiers in immunology · 2022Article
- The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.Endocrine reviews · 2021Review
- Identifying the lungs as a susceptible site for allele-specific regulatory changes associated with type 1 diabetes risk.Communications biology · 2021Article
- The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children.International journal of molecular sciences · 2021Review
- Untangling the genetic link between type 1 and type 2 diabetes using functional genomics.Scientific reports · 2021Article
- De-coding genetic risk variants in type 1 diabetes.Immunology and cell biology · 2021Review
- The RNA-binding profile of the splicing factor SRSF6 in immortalized human pancreatic β-cells.Life science alliance · 2021Article
- Novel genetic risk factors influence progression of islet autoimmunity to type 1 diabetes.Scientific reports · 2020Article
- Transcription factor GLIS3: Critical roles in thyroid hormone biosynthesis, hypothyroidism, pancreatic beta cells and diabetes.Pharmacology & therapeutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
objectiveThe purpose of this study was to explore whether non-human leukocyte antigen (non-HLA) genetic markers can improve type 1 diabetes(T1D) prediction in a prospective cohort with high-risk HLA-DR,DQ genotypes.
methodsThe Diabetes Autoimmunity Study in the Young (DAISY) follows prospectively for the development of T1D and islet autoimmunity (IA)children at increased genetic risk. A total of 1709 non-Hispanic White DAISY participants have been genotyped for 27 non-HLA single nucleotide polymorphisms (SNPs) and one microsatellite.
resultsIn multivariate analyses adjusting for family history and HLA-DR3/4 genotype, PTPN22 (rs2476601) and two UBASH3A (rs11203203 and rs9976767) SNPs were associated with development of IA [hazard ratio(HR)=1.87, 1.55, and 1.54, respectively, all p ≤ 0.003], while GLIS3 and IL2RA showed borderline association with development of IA. INS,UBASH3A, and IFIH1 were significantly associated with progression from IA to diabetes (HR=1.65, 1.44, and 1.47, respectively, all p ≤ 0.04), while PTPN22 and IL27 showed borderline association with progression from IA to diabetes. In survival analysis, 45% of general population DAISY children with PTPN22 rs2476601 TT or HLA-DR3/4 and UBASH3A rs11203203 AA developed diabetes by age 15, compared with 3% of children with all other genotypes (p<0.0001). Addition of non-HLA markers to HLA-DR3/4,DQ8 did not improve diabetes prediction in first-degree relatives.
conclusionAddition of PTPN22 and UBASH3A SNPs to HLA-DR,DQ genotyping can improve T1D risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.